Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.

Clinical and Vaccine Immunology : CVI
Rebecca A BradyDrusilla L Burns

Abstract

The licensed anthrax vaccine and many of the new anthrax vaccines being developed are based on protective antigen (PA), a nontoxic component of anthrax toxin. For this reason, an understanding of the immune response to PA vaccination is important. In this study, we examined the antibody response elicited by PA-based vaccines and identified the domains of PA that contribute to that response in humans as well as nonhuman primates (NHPs) and rabbits, animal species that will be used to generate efficacy data to support approval of new anthrax vaccines. To this end, we developed a competitive enzyme-linked immunosorbent assay (ELISA), using purified recombinant forms of intact PA and its individual domains. We found that PA-based vaccines elicited IgG antibodies to each of the four PA domains in all three species. We also developed a competitive toxin neutralization assay, which showed that rabbits, NHPs, and humans all have functional antibody populations that bind to domains 1, 3, and 4. While the domain specificities of the antibody responses elicited by PA-based vaccines were similar in humans, NHPs, and rabbits, competitive assays suggested that humans may have a more significant secondary population of IgG antibodies that bin...Continue Reading

References

Feb 14, 1992·Journal of Immunological Methods·C Schwab, H R Bosshard
Oct 14, 1970·Journal of Molecular Biology·M Mandel, A Higa
Feb 27, 1997·Nature·C PetosaR C Liddington
Sep 4, 1999·Journal of Applied Microbiology·M L PittA M Friedlander
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Dec 12, 2001·Vaccine·P R PittmanA M Friedlander
Sep 13, 2002·Current Topics in Microbiology and Immunology·A M FriedlanderB E Ivins
Oct 25, 2002·Emerging Infectious Diseases·Daniel B JerniganUNKNOWN National Anthrax Epidemiologic Investigation Team
Oct 23, 2003·Annual Review of Cell and Developmental Biology·R John Collier, John A T Young
Aug 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·D Borden LacyR John Collier
Dec 14, 2004·Microbiology and Molecular Biology Reviews : MMBR·Andrew J PhippsMichael D Lairmore
Aug 16, 2006·Journal of Applied Microbiology·L W J Baillie
Aug 21, 2007·Molecular Immunology·Jianhui ZhouDonald C Reason
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John D Grabenstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.